Research ArticleAccepted Article
Open Access
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie Harrold, Sven Richter, Benoit Guerette and Philip J. Mease
The Journal of Rheumatology November 2020, jrheum.191209; DOI: https://doi.org/10.3899/jrheum.191209
Alexis Ogdie
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Mei Liu
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Meghan Glynn
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Kelechi Emeanuru
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Leslie Harrold
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Sven Richter
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Benoit Guerette
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Philip J. Mease
From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine. This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results. Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating. Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB. Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB. A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington. Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Article Information
jrheum.191209
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online November 15, 2020.
Article Versions
- You are currently viewing a Latest version of this article (November 15, 2020 - 04:00).
- latest version (March 1, 2021 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Alexis Ogdie,
- Mei Liu,
- Meghan Glynn,
- Kelechi Emeanuru,
- Leslie Harrold,
- Sven Richter,
- Benoit Guerette and
- Philip J. Mease
- From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Corrona, LLC, Waltham, Massachusetts; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Global Medical Affairs, Amgen Inc.; Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine.
This study was sponsored by Corrona, LLC, and the analysis was funded by Celgene Corporation. Amgen acquired the worldwide rights to Otezla® (apremilast) on November 21, 2019. Access to study data was limited to Corrona, and Corrona statisticians completed all of the analysis; all authors contributed to the interpretation of the results.
Ethical conduct: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central investigational review board (New England Independent Review Board, NEIRB No. 120160610); there were more than 50 study sites. For academic investigative sites that did not receive a waiver to use the central investigational review board, full board approval was obtained from the respective governing investigational review boards and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry patients were required to provide written informed consent before participating.
Conflicts of interest: A. Ogdie has received grant/research support from Pfizer Inc and Novartis and has served as a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Corrona, Eli Lilly and Company, Novartis, Pfizer Inc, and Takeda. M. Liu, M. Glynn, and K. Emeanuru have worked on Corrona contracted subscriptions for AbbVie, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Regeneron, Roche, Merck, UCB, and Valeant. L. R. Harrold is an employee and shareholder of Corrona, LLC, received grants from Pfizer Inc, and has served as a consultant to AbbVie, Bristol-Myers Squibb and Roche. S. Richter and B. Guerette are employees of Amgen Inc. and were employees of Celgene Corporation at the time of study conduct. P. J. Mease has received grant/research support from and served as a consultant for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Genentech, Janssen, Novartis, Pfizer Inc, Roche, and UCB, and has served on the speakers bureau for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Janssen, Pfizer Inc, and UCB.
Corrona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sanofi, Sun, and UCB.
A. Ogdie, MD, Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. Liu, PhD, Corrona, LLC, Waltham, Massachusetts; M. Glynn, MS, Corrona, LLC, Waltham, Massachusetts; K. Emeanuru, MPH, Corrona, LLC, Waltham, Massachusetts; L. Harrold, MD, MPH, Corrona, LLC, Waltham, Massachusetts, and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; S. Richter, MD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; B. Guerette, PhD, Global Medical Affairs, Amgen Inc., Thousand Oaks, California; P. J. Mease, MD, Division of Rheumatology Clinical Research, Swedish Medical Center/Providence St. Joseph Health, and Division of Rheumatology, University of Washington School of Medicine, Seattle, Washington.
Address correspondence to: Alexis Ogdie, MD, 3400 Spruce Street, 5 White Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Tel.: 215-662-4500. Email: alogdie@pennmedicine.upenn.edu.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie Harrold, Sven Richter, Benoit Guerette, Philip J. Mease
The Journal of Rheumatology Nov 2020, jrheum.191209; DOI: 10.3899/jrheum.191209
Accepted manuscript
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie Harrold, Sven Richter, Benoit Guerette, Philip J. Mease
The Journal of Rheumatology Nov 2020, jrheum.191209; DOI: 10.3899/jrheum.191209